Zobrazeno 1 - 10
of 247
pro vyhledávání: '"Matthew T, Campbell"'
Autor:
Mihir D. Shanker, Zhiqian Henry Yu, Jinzhong Yang, Surena Matin, Matthew T. Campbell, Pavlos Msaouel, Nizar Tannir, Surendra Prajapati, Yao Ding, Belinda Lee, Angela Sobremonte, Chad Tang
Publikováno v:
BJUI Compass, Vol 5, Iss 10, Pp 913-915 (2024)
Externí odkaz:
https://doaj.org/article/ec3fbc5de47645f68d5c19768cea6592
Autor:
Mohammad Jad Moussa, Jaanki Khandelwal, Nathaniel R. Wilson, Sagar A. Naik, Vivek Subbiah, Matthew T. Campbell, Pavlos Msaouel, Parminder Singh, Omar Alhalabi
Publikováno v:
Current Oncology, Vol 31, Iss 6, Pp 3342-3349 (2024)
Small cell bladder cancer (SCBC) is a rare and aggressive disease, often treated with platinum/etoposide-based chemotherapy. Key molecular drivers include the inactivation of onco-suppressor genes (TP53, RB1) and amplifications in proto-oncogenes (MY
Externí odkaz:
https://doaj.org/article/bbb72ef7a31447418f0648f931ce0d61
Autor:
Patrick Carriere, Omar Alhalabi, Jianjun Gao, Osama Mohamad, Matthew T. Campbell, Amishi Shah, Sangeeta Goswami, Kelly Bree, Byron Lee, Neema Navai, Henry Mok, Lauren Mayo, Charles Guo, Quynh Nguyen, Sean McGuire, Ryan Park, Shalin Shah, Karen Hoffman, Steven Frank, Chad Tang, Seungtaek Choi, Ashish Kamat, Comron Hassanzadeh
Publikováno v:
Clinical and Translational Radiation Oncology, Vol 49, Iss , Pp 100866- (2024)
Purpose: Trimodality therapy for muscle-invasive bladder cancer (MIBC) yields similar oncologic outcomes compared to radical cystectomy in appropriately selected patients; however, data regarding locally advanced MIBC (LA-MIBC) is limited. We explore
Externí odkaz:
https://doaj.org/article/07cb8394281b4779b3398db3f3a3c52d
Autor:
Sang T. Kim, Yanshuo Chu, Mercy Misoi, Maria E. Suarez-Almazor, Jean H. Tayar, Huifang Lu, Maryam Buni, Jordan Kramer, Emma Rodriguez, Zulekha Hussain, Sattva S. Neelapu, Jennifer Wang, Amishi Y. Shah, Nizar M. Tannir, Matthew T. Campbell, Don L. Gibbons, Tina Cascone, Charles Lu, George R. Blumenschein, Mehmet Altan, Bora Lim, Vincente Valero, Monica E. Loghin, Janet Tu, Shannon N. Westin, Aung Naing, Guillermo Garcia-Manero, Noha Abdel-Wahab, Hussein A. Tawbi, Patrick Hwu, Isabella C. Glitza Oliva, Michael A. Davies, Sapna P. Patel, Jun Zou, Andrew Futreal, Adi Diab, Linghua Wang, Roza Nurieva
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-1 (2024)
Externí odkaz:
https://doaj.org/article/c777865947454d67bd544bb4094e3d5f
Autor:
Jose A. Karam, Pavlos Msaouel, Cara L. Haymaker, Surena F. Matin, Matthew T. Campbell, Amado J. Zurita, Amishi Y. Shah, Ignacio I. Wistuba, Enrica Marmonti, Dzifa Y. Duose, Edwin R. Parra, Luisa Maren Solis Soto, Caddie Laberiano-Fernandez, Marisa Lozano, Alice Abraham, Max Hallin, Curtis D. Chin, Peter Olson, Hirak Der-Torossian, Xiaohong Yan, Nizar M. Tannir, Christopher G. Wood
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-14 (2023)
Abstract Sitravatinib is an immunomodulatory tyrosine kinase inhibitor that can augment responses when combined with programmed death-1 inhibitors such as nivolumab. We report a single-arm, interventional, phase 2 study of neoadjuvant sitravatinib in
Externí odkaz:
https://doaj.org/article/8affada371c5430f97f977800c38a734
Publikováno v:
Biomedicines, Vol 12, Iss 3, p 519 (2024)
Cisplatin-based chemotherapy has been the standard of care in metastatic urothelial cancer (mUC) for more than two decades. However, many patients with comorbidities cannot receive cisplatin or its alternative, carboplatin. ‘Cisplatin-ineligible’
Externí odkaz:
https://doaj.org/article/377a74046c09489887e9cdd18dbe7230
Autor:
Sang T. Kim, Yanshuo Chu, Mercy Misoi, Maria E. Suarez-Almazor, Jean H. Tayar, Huifang Lu, Maryam Buni, Jordan Kramer, Emma Rodriguez, Zulekha Hussain, Sattva S. Neelapu, Jennifer Wang, Amishi Y. Shah, Nizar M. Tannir, Matthew T. Campbell, Don L. Gibbons, Tina Cascone, Charles Lu, George R. Blumenschein, Mehmet Altan, Bora Lim, Vincente Valero, Monica E. Loghin, Janet Tu, Shannon N. Westin, Aung Naing, Guillermo Garcia-Manero, Noha Abdel-Wahab, Hussein A. Tawbi, Patrick Hwu, Isabella C. Glitza Oliva, Michael A. Davies, Sapna P. Patel, Jun Zou, Andrew Futreal, Adi Diab, Linghua Wang, Roza Nurieva
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-19 (2022)
Abstract Immune checkpoint inhibitors are associated with immune-related adverse events (irAEs), including arthritis (arthritis-irAE). Management of arthritis-irAE is challenging because immunomodulatory therapy for arthritis should not impede antitu
Externí odkaz:
https://doaj.org/article/eafab2babacd4730b744815d6b4763df
Autor:
Omar Alhalabi, Jianfeng Chen, Yuxue Zhang, Yang Lu, Qi Wang, Sumankalai Ramachandran, Rebecca Slack Tidwell, Guangchun Han, Xinmiao Yan, Jieru Meng, Ruiping Wang, Anh G. Hoang, Wei-Lien Wang, Jian Song, Lidia Lopez, Alex Andreev-Drakhlin, Arlene Siefker-Radtke, Xinqiao Zhang, William F. Benedict, Amishi Y. Shah, Jennifer Wang, Pavlos Msaouel, Miao Zhang, Charles C. Guo, Bogdan Czerniak, Carmen Behrens, Luisa Soto, Vassiliki Papadimitrakopoulou, Jeff Lewis, Waree Rinsurongkawong, Vadeerat Rinsurongkawong, Jack Lee, Jack Roth, Stephen Swisher, Ignacio Wistuba, John Heymach, Jing Wang, Matthew T. Campbell, Eleni Efstathiou, Mark Titus, Christopher J. Logothetis, Thai H. Ho, Jianjun Zhang, Linghua Wang, Jianjun Gao
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-12 (2022)
The deficiency of MTAP, an enzyme of the adenine salvage pathway, occurs in some cancers. Here the authors perform a small cohort phase II clinical trial with metastatic MTAP-deficient urothelial cancer (UC) and show an increased overall response whe
Externí odkaz:
https://doaj.org/article/7a4eb434bab9460784c2152084c1035e
Autor:
Omar Alhalabi, Matthew T. Campbell, Lianchun Xiao, Ana C. Adriazola, Nathaniel R. Wilson, Arlene O. Siefker‐Radtke, Paul G. Corn, Amado Zurita, Eric Jonasch, Jianjun Gao, Mehrad Adibi, Ashish M. Kamat, Neema Navai, Louis L. Pisters, Colin Dinney, Surena F. Matin, Amishi Y. Shah
Publikováno v:
BJUI Compass, Vol 3, Iss 1, Pp 37-44 (2022)
Abstract Objectives Multimodal kidney‐preserving (MKP) strategies may be an option for patients with localised or locally advanced high‐risk upper tract urothelial carcinoma (UTUC) who have a relative contraindication for nephroureterectomy (NU).
Externí odkaz:
https://doaj.org/article/4bec1710d1984582ada90fc20a09d76b
Autor:
Matthew T. Campbell, Surena F. Matin, Alda L. Tam, Rahul A. Sheth, Kamran Ahrar, Rebecca S. Tidwell, Priya Rao, Jose A. Karam, Christopher G. Wood, Nizar M. Tannir, Eric Jonasch, Jianjun Gao, Amado J. Zurita, Amishi Y. Shah, Sonali Jindal, Fei Duan, Sreyashi Basu, Hong Chen, Alexsandra B. Espejo, James P. Allison, Shalini S. Yadav, Padmanee Sharma
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-12 (2021)
Anti-CTLA4 therapy has not been comprehensively explored for the treatment of metastatic renal cell carcinoma (mRCC). Here, in a pilot study of anti-CTLA4 therapy with or without cryoablation in mRCC, the authors report that the combination is feasib
Externí odkaz:
https://doaj.org/article/204efb116032411484ebc80c52f409dc